Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

ts during therapy and for 6 months after completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneum
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Research and Markets( ... "Future Horizons and Growth Strategies in the ... Country Forecasts" report to their offering. ... European Blood Banking Market 2015 is a new ... suppliers and potential market entrants identify and evaluate ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take ... and will feature the abstracts as two oral presentations and ... and the poster session will address the prevalence of gout ...
... BROOMFIELD, Colo., April 28, 2011 Biodesix announces the ... of the Addario Lung Cancer Medical Institute (ALCMI, pronounced ... Cancer) study is recruiting a minimum of 250 subjects ... in the United States. The study collects biospecimens and ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Biodesix Supports Unique Lung Cancer Research Initiative 2Biodesix Supports Unique Lung Cancer Research Initiative 3
(Date:7/2/2015)... ... July 02, 2015 , ... Patton State ... of State Hospitals. Prior to using Winscribe’s dictation and clinical documentation solutions, Patton ... to manage their organization’s dictation and transcription processes. , Over the ...
(Date:7/1/2015)... ... ... In the United States, summer has always been the season to travel ... Dubai, the summer temperatures are so hot, that July vacationers often leave their home ... ORA Dentistry Spa notes that a trip to the United States, and Los Angeles ...
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... ... July 01, 2015 , ... A healthy eating ... chickens and eggs. Eating organic foods and products can help limit the exposure ... friendly than production chicken farming. Choosing home raised chickens and eggs that do ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will ... of America (HCA), as it further expands its Strategic Alliance Partnership Program for ... this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon ...
Breaking Medicine News(10 mins):Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 3Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... , TUESDAY, Oct. 25 (HealthDay News) -- ... have a major effect on the rate at which ... The study included 144 experienced U.S. male pilots over ... Administration-approved flight simulator test three times over two years. ...
... as angiotensin-receptor blockers could reduce risk of mortality in ... (AS) by 30 per cent over an eight-year period, ... delegates at the Canadian Cardiovascular Congress. The condition is ... shifts how we think about AS by looking at ...
... MONDAY, Oct. 24 (HealthDay News) -- Teens who drink lots ... suggests. But the study authors concede that sodas are ... there,s a chance that the sugar and caffeine from carbonated ... not a cause-and-effect. Soda consumption, for example, may be a ...
... MONDAY, Oct. 24 (HealthDay News) -- Cancer-causing strains of ... for heart disease, even if she doesn,t have any ... suggests. It,s the first investigation of a possible ... of the most common sexually transmitted pathogens in the ...
... A model used to estimate breast cancer survival rates found ... will avoid a breast cancer death because of screening mammography ... published Online First by Archives of Internal Medicine , ... likely to know a cancer survivor than ever before," the ...
... D.C. Pat Furlong founded Parent Project Muscular Dystrophy (PPMD) ... affected by muscular dystrophy with both resources and hope. Now, ... end the disease. She has spearheaded a partnership between PPMD ... open-access publication, PLoS Currents: Muscular Dystrophy, this month. The story ...
Cached Medicine News:Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 3Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 2Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 3Health News:Could HPV Raise Women's Risk for Heart Disease? 2Health News:Could HPV Raise Women's Risk for Heart Disease? 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 2Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 4Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
... capsular bag in cases of damaged or ... for scleral fixation with suture. Robert J. ... recognized from his early experience using the ... need for greater stability when confronted with ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Medicine Products: